Precigen Inc. (PGEN)
1.97
-0.06 (-2.96%)
At close: Feb 20, 2025, 3:59 PM
1.99
1.27%
After-hours: Feb 20, 2025, 06:38 PM EST
undefined% (undefined)
| Bid | 1.92 |
| Market Cap | 575.49M |
| Revenue (ttm) | - |
| Net Income (ttm) | - |
| EPS (ttm) | -0.54 |
| PE Ratio (ttm) | -3.64 |
| Forward PE | n/a |
| Analyst | Strong Buy |
| Ask | 2.02 |
| Volume | 1,357,105 |
| Avg. Volume (20D) | 1,864,518 |
| Open | 2.00 |
| Previous Close | 2.03 |
| Day's Range | 1.90 - 2.06 |
| 52-Week Range | 0.65 - 2.17 |
| Beta | undefined |
About PGEN
Precigen, Inc. discovers and develops the next generation of gene and cellular therapies in the United States. It also provides disease-modifying therapeutics; genetically engineered swine for regenerative medicine applications; and reproductive and embryo transfer technologies. In addition, the company offers UltraVector platform that incorporates advanced DNA construction technologies and computational models to design and assemble genetic comp...
Industry Biotechnology
Sector Healthcare
IPO Date Aug 8, 2013
Employees 202
Stock Exchange NASDAQ
Ticker Symbol PGEN
Website https://www.precigen.com
Analyst Forecast
According to 5 analyst ratings, the average rating for PGEN stock is "Strong Buy." The 12-month stock price forecast is $6, which is an increase of 205.34% from the latest price.
Buy 80.00%
Hold 0.00%
Sell 20.00%
Next Earnings Release
Precigen Inc. is scheduled to release its earnings on Mar 18, 2025,
during market hours.
Analysts project revenue of ... Unlock content with Pro Subscription
Analysts project revenue of ... Unlock content with Pro Subscription
4 weeks ago
+18.58%
Precigen shares are trading higher after HC Wainwr...
Unlock content with
Pro Subscription
1 month ago
+28.47%
Precigen shares are trading higher after the company announced it's seeking FDA priority review for its gene therapy targeting rare respiratory disease.
